TransMedics initiated with a Hold at Stifel

 Stifel initiated coverage of TransMedics (TMDX) with a Hold rating and $115 price target The firm would characterize results of its survey of 19 U.S. transplant surgeons survey as “mixed,” reporting surgeon feedback suggests TransMedics’ OCS portable organ perfusion, optimization, and monitoring system may face market share pressure, driven by competition. When factoring in the mixed survey findings, the firm believe risk-reward is balanced at current levels against its “confidence in meaningful upside potential to estimates,” the analyst tells investors.

https://www.msn.com/en-us/money/companies/transmedics-initiated-with-a-hold-at-stifel/ar-AA1LOYy3